Neoadjuvant Programmed Cell Death Protein 1 and Chemotherapy in Combination in Muscle-Invasive Urothelial Cancer: Promising, But Not Deserving to Try Further

Affiliations

Comment

Sheng Zhang. J Clin Oncol. 2022.

. 2022 Aug 10;40(23):2656.

doi: 10.1200/JCO.22.00420. Epub 2022 May 24.

¹ Sheng Zhang, MD, Shanghai Cancer Center and Shanghai Medical College, Fudan University, Shanghai, China.

No abstract available

Comment in

Reply to S. Zhang.
Lattanzi M, Funt SA, Rosenberg JE. Lattanzi M, et al. J Clin Oncol. 2022 Aug 10;40(23):2657-2658. doi: 10.1200/JCO.22.00809. Epub 2022 May 24. J Clin Oncol. 2022. PMID: 35609227 No abstract available.

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, Apollo A, Durdin TD, Truong H, Kamradt J, Khalil M, Lash B, Ostrovnaya I, McCoy AS, Hettich G, Regazzi A, Jihad M, Ratna N, Boswell A, Francese K, Yang Y, Folefac E, Herr HW, Donat SM, Pietzak E, Cha EK, Donahue TF, Goh AC, Huang WC, Bajorin DF, Iyer G, Bochner BH, Balar AV, Mortazavi A, Rosenberg JE. Funt SA, et al. J Clin Oncol. 2022 Apr 20;40(12):1312-1322. doi: 10.1200/JCO.21.01485. Epub 2022 Jan 28. J Clin Oncol. 2022. PMID: 35089812 Free PMC article. Clinical Trial.